Phenotypic characterization of patients with early-onset high myopia due to mutations in COL2A1 or COL11A1: Why not Stickler syndrome?

Lin Zhou,1 Xueshan Xiao,1 Shiqiang Li,1 Xiaoyun Jia,1 Panfeng Wang,1 Wenmin Sun,1 Fengsheng Zhang,2 Jiazhang Li,3 Tuo Li,3 Qingjiong Zhang1

1State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, China; 2Huhehaote Chaoju Eye Hospital, Huhehaote, China; 3Central Hospital of Enshi Autonomous Prefecture, Enshi Central College of Wuhan University, Enshi, China

Purpose: Our previous study reported that 5.5% of probands with early-onset high myopia (eoHM) had mutations in COL2A1 or COL11A1. Why were the probands initially considered to have eoHM but not Stickler syndrome (STL)?

Methods: Probands and family members with eoHM and mutations in COL2A1 or COL11A1 were followed up and reexamined based on the criteria for STL. Further comprehensive examinations were conducted for patients with eoHM and mutations in COL2A1 or COL11A1 and controls with eoHM without mutations in COL2A1 or COL11A1. We performed comparisons between probands, affected family members with mutations in COL2A1 or COL11A1, and controls with eoHM without mutations in COL2A1 or COL11A1.

Results: Twelve probands (8.91±4.03 years) and 14 affected family members (37.00±11.18 years) with eoHM and mutations in COL2A1 or COL11A1, as well as 30 controls with eoHM but without mutations in COL2A1 or COL11A1, were recruited. Among them, 25.0% of probands and 50.0% of affected family members met the diagnostic criteria for STL after reexamination. Posterior vitreous detachment/foveal hypoplasia (PVD/FH), hypermobility of the elbow joint (HJ), and vitreous opacity were more frequent in patients with eoHM with mutations in COL2A1 or COL11A1 than in the controls (p = 1.40 × 10−5, 3.72 × 10−4, 2.30× 10−3, respectively). HJ was more common in the probands than in the affected family members (11/12 versus 3/14; p = 3.42 × 10−4), suggesting age-dependent manifestation. EoHM presented in all the probands and in 11/14 affected family members, suggesting that it is a more common indicator of STL than the previously described vitreoretinal abnormalities, especially in children. The rate of STL diagnosis could increase from 25.0% to 66.7% for probands and from 50.0% to 92.9% for affected family members if eoHM, PVD/FH, and HJ are added to the diagnostic criteria.

Conclusions: In summary, it is not easy to differentiate STL from eoHM with routine ocular examination in outpatient clinics. Awareness of atypical phenotypes and newly recognized signs may be of help in identifying atypical STL, especially in children at eye clinics.

Early-onset high myopia (eoHM), defined as a spherical refraction of less than or equal to −6.0 diopters (D) in each meridian [1] or an axial length of at least 26 mm in both eyes [2], occurs before 7 years of age [3-5]. Compared to other types of myopia, eoHM is more likely to be determined by genetic factors due to minimal effects of the environment [4,6,7], such as extensive near work, that plays an important role in common or late-onset high myopia [8,9]. Thus far, the genetic defects known to cause HM have been identified in only a small number of families, based on our previous studies [5,10-12]. However, mutations in the genes known to be responsible for retinal diseases were found in about one-fourth of probands with eoHM in a comprehensive analysis of whole-exome sequencing data from 298 families [4]. These findings were further confirmed with an analysis of whole-exome sequencing data from another eoHM cohort of 325 families [7]. For those families with eoHM and mutations in RetNet genes, approximately one-fifth (34 probands) had mutations in the genes responsible for Stickler syndrome (STL), including COL2A1 (Gene ID 1280, OMIM 120140) or COL11A1 (Gene ID 1301, OMIM 120280). It is of interest to investigate the phenotypic characteristics of patients with eoHM with mutations in genes associated with STL.

STL is a group of genetic disorders involving the collagen of connective tissue, notable mainly in the face, joints, ears, and eyes; STL affects an estimated 1 in 7,500 to 9,000 newborns [11,13]. Marshall syndrome, caused by mutations in COL11A1, is considered a variant of STL [14-16]. STL can be transmitted as an autosomal dominant or autosomal recessive
trait. The autosomal dominant form of STL is caused by mutations in COL2A1 [17], COL11A1 [18], or COL11A2 (Gene ID 1302, OMIM 120290) [19], while the autosomal recessive form of STL is caused by mutations in COL9A1 (Gene ID 12839, OMIM 120210) [20], COL9A2 (Gene ID 1298, OMIM 120260) [21], COL9A3 (Gene ID 1299, OMIM 120270) [22], or LOXL3 (Gene ID 84695, OMIM 607163) [23,24]. STL type 1 (STL1), the most common subtype of STL, accounting for 80–90% of all STL cases, is caused by mutations in COL2A1. STL type 2 (STL2) is caused by mutations in COL11A1; it accounts for 10–20% of all STL cases [13]. Truncation mutations or missense mutations affecting glycine are the main class of the pathogenic mutations of COL2A1 or COL11A1 [4,25]. The manifestation of STL is multisystemic, and includes ocular findings of characteristic vitreous opacity, myopia, cataract, and retinal detachment, hearing loss, midfacial dysplasia and cleft palate (either alone or as part of the Robin sequence), mild spondyloepiphyseal dysplasia, and precocious arthritis [26,27]. The presence and severity of each sign may vary greatly from patient to patient and change over time [28,29]. Additionally, STL type 3, caused by mutations in COL11A2, may have no eye involvement [30,31]. Mutations in exon 2 of COL2A1 have been suggested to affect mainly ocular phenotypes with minimal or the absence of systemic involvement [32-34]. The diagnosis of STL may not be easy even with the diagnostic criteria that were created for this syndrome in 2005 [27]. Previously, genotype–phenotype studies were based mainly on analyses of patients with STL. Extended genotype–phenotype analysis based on patients with individual major signs, such as eoHM [27], may detect patients with atypical phenotypes, but such studies have been rare.

In this study, follow-up reexaminations were performed on probands and their affected family members with eoHM and mutations in COL2A1 or COL11A1 to reveal why these probands were initially considered to have eoHM but not STL. In addition, we wanted to know whether any specific ocular or systemic signs could warrant further examination of atypical STL in childhood with major presenting signs of eoHM.

METHODS

Participants: This study is part of our ongoing project on the genetics of eoHM. Based on whole-exome sequencing, potential pathogenic mutations were previously identified in 34 of the 623 probands with eoHM [4,7] in two of the six genes known to cause STL (i.e., COL2A1 and COL11A1). Of the 34 families with mutations, 12 probands (Table 1) and 14 affected family members were available for follow-up reexamination in the present study. Meanwhile, 30 recently identified probands with eoHM without mutations in the six genes but with comparable clinical data were analyzed as controls. Written informed consent conforming to the tenets of the Declaration of Helsinki and adhering to the ARVO statement on human subjects was obtained from the participants or their guardians before the collection of blood samples and clinical data. This study was approved by the institutional review board of Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, China. Clinical evaluation: The participants described above received ocular and systemic evaluations based on the diagnostic criteria for STL [27]. Refractive error was measured with an autorefractometer (Topcon KR-8000, Paramus, NJ) after mydriasis using compound tropicamide (Mydrin-P, Santen Pharmaceutical, Osaka, Japan). Axial length was measured using an optical biometer (IOL master V5.0, Carl Zeiss Meditec AG, Oberkohlen, Germany). Photographs of the anterior vitreous opacity were taken with a photo slit-lamp microscope (LS-6, Chongqing, China). Fundus photographs were obtained using a digital retinal camera (CR-2 PLUS AF, Canon, Tokyo, Japan). The posterior vitreoretinal and macular regions were examined using optical coherence tomography (OCT; Topcon Corp, Oakland, NJ).

Examinations of the orofacial, auditory, and musculoskeletal systems were also performed. Pure-tone audiometry (GSI 61, GSI, Eden Prairie, MN), the air conduction threshold (0.25–8 kHz), and the angles of elbow and knee hypermobility were evaluated for all 12 probands and their 14 affected family members. X-ray examinations (Luminors Select, SIEMENS, Munich, Germany) were conducted on select individuals with complaints of discomfort in their joints or on individuals recommended for such examinations by professional physicians.

Overview of the genotype–phenotype: To understand the extent of phenotypic variation in eoHM associated with mutations in COL2A1 and COL11A1, the reported phenotypes of STL caused by mutations in these two genes were reviewed and summarized based on the published literature [15,17,18,25,27-29,32,35-90], which were retrieved from PubMed, Web of Science, and Google Scholar (Appendix 1). The phenotypes of the present cases were discussed based on comparison with the reported overview phenotypes of STL. Statistical analysis: Clinical data for patients with eoHM with or without mutations in COL2A1 or COL11A1 were compared first. For patients with eoHM with mutations in COL2A1 or COL11A1, the clinical data for the probands were compared to the data for affected family members. A t test and Fisher’s exact test were performed in SPSS 22.0 (SPSS, Inc., Chicago,
Table 1. Pathogenic mutations of COL2A1 or COL11A1 detected in the 12 probands with eOHM.

| Gene  | Patient ID | Chr | Position | Exon/Position | Intron | Nucleotide Change | Amino Acid Change | Status | Computational Prediction | dbSNP ID | Novel or Reported |
|-------|------------|-----|----------|---------------|--------|-------------------|-------------------|--------|--------------------------|----------|-------------------|
| **COL2A1** |            |     |          |               |        |                   |                   |        |                          |          |                   |
| HM992 | chr12      | 48,380,410 | Exon 45 | c.3138delT    |        |                   | p.P1046fs         | Het    |                          | rs121912873 | Novel             |
| HM304 | chr12      | 48,380,792 | IVS 44  | c.3111+1G>A   |        |                   |                   | Het    | DL                       |          | Reported           |
| HM894 | chr12      | 48,380,855 | Exon 44 | c.3049delG    |        |                   | p.G1017fs         | Het    |                          |          | Novel             |
| HM862 | chr12      | 48,372,481 | Exon 42 | c.2794C>T     |        |                   | p.R932*           | Het    |                          | rs121912866 | Reported          |
| HM918 | chr12      | 48,375,892 | Exon 33 | c.2128C>T     |        |                   | p.R785*           | Het    |                          |          | Reported           |
| HM842 | chr12      | 48,377,504 | Exon 30 | c.1957C>T     |        |                   | p.R653*           | Het    |                          | rs121912893 | Reported          |
| HM951 | chr12      | 48,377,504 | Exon 30 | c.1957C>T     |        |                   | p.R653*           | Het    |                          | rs121912893 | Reported          |
| HM849 | chr12      | 48,378,777 | IVS 27  | c.1833+1G>A   |        |                   |                   | Het    | SSA                     |          | None               |
| HM1000| chr12      | 48,379,358 | Exon 26 | c.1693C>T     |        |                   | p.R565C           | Het    | PrD                      | rs121912884 | Reported          |
| HM820 | chr12      | 48,380,672 | IVS 21  | c.1366–1G>C   |        |                   |                   | Het    | SSA                     |          | None               |
| **COL11A1** |            |     |          |               |        |                   |                   |        |                          |          |                   |
| HM813 | chr01      | 103,355,027 | Exon 59 | c.4484G>A     |        |                   | p.G1495E          | Het    | PrD                      |          | Reported           |
| HM878 | chr01      | 103,385,883 | Exon 49 | c.3782G>T     |        |                   | p.G1261V          | Het    | PrD                      |          | Reported           |

Note: these mutations were not present in the 1000G, EVS, or ExAC databases. Chr, chromosome; Het, heterozygous; PPH2, PolyPhen-2, not applicable for truncation mutations; DL, donor loss; SSA, splicing site abolished; PrD, probably damaging; D, damaging; PPH2, PolyPhen; BDGP; SIFT; 1000G; EVS.
IL). A p value of less than 0.05 was considered statistically significant (the hypothesis tests were two-sided).

RESULTS
Of the 34 eoHM families with mutations in COL2A1 or COL11A1, 26 patients from 12 families received follow-up examinations, including 12 probands and 14 affected family members (Figure 1). Of the 26 patients, 23 were from ten families with mutations in COL2A1, and three were from two families with mutations in COL11A1 (Table 1 and Appendix 2). No patients in this cohort had mutations in exon 2 of COL2A1 (Table 1).

The medical records from the initial visits of the 12 probands with mutations in COL2A1 or COL11A1 did not

Figure 1. Pedigrees of 12 families with mutations and cosegregation results for those mutations. The family members and their corresponding mutations are shown just above the pedigrees (M, mutated allele; +, wild-type allele). Squares indicate male individuals, and circles indicate female individuals. The patients with arrows were the probands in these families.
mention specific signs that could lead to a diagnosis of STL rather than eoHM. However, comprehensive follow-up reexaminations, based on STL diagnostic criteria [27], identified additional ocular and systemic signs in some of the probands and their affected family members (Appendix 2). Based on clinical data obtained in the reexaminations, a diagnosis of STL could be made in 25.0% (3/12) of the probands and 50% (7/14) of the affected family members, following the reported diagnostic criteria [27] (Figure 2 and Figure 3; Appendix 2).

Comparing the 26 patients with eoHM harboring mutations in COL2A1 or COL11A1 with the 30 patients with eoHM without mutations in COL2A1 or COL11A1 (Table 2 and Appendix 2), there were statistically significant differences in posterior vitreous detachment and/or foveal hypoplasia (PVD/FH; 22/26 versus 8/30; \( p = 1.40 \times 10^{-5} \); Figure 2), hypermobility of the elbow joints (HJ; 16/26 versus 3/30; \( p = 3.72 \times 10^{-4} \)), and vitreous opacity (9/26 vs. 1/30, \( p = 2.30 \times 10^{-3} \)). For all patients less than 14 years old, hypermobility of the elbow joints (Figure 3) was present in all 12 patients with eoHM with mutations in COL2A1 or COL11A1 but in only three of the 18 patients with eoHM without mutations in COL2A1 or COL11A1 (\( p = 8.00 \times 10^{-6} \)). Between the two cohorts, there were no significant differences in the presence of HM, the degree of refractive error, the axial length,

Figure 2. Ocular manifestations of patients with mutations in COL2A1 or COL11A1. A: Photographs of the anterior segments of HM849IV2, HM849III3, HM849III4, and HM878II3. Membrane and beaded vitreous opacity and cataracts can be seen in HM849IV2, and membrane vitreous opacity can be seen in HM849III3. Cataracts can be seen in HM849IV2 and HM849III4, while HM878II3 is normal. B: Multidirectional wide-field color photographs of HM849II13 and HM813I2, and B-scans of the left eyes of HM862II13 and HM470II11. Retinal degeneration can be seen in HM849III3, but not in HM813I2. On the B-scans of HM862II13 and HM470II11, retinal detachment and vitreous opacity, respectively, can be seen. C: OCT scans of HM849II13, HM862II11, and HM878II3. Posterior vitreous detachment and foveal hypoplasia (the remaining layers in the central fovea of the macula, including the inner limiting membrane, the nerve fiber layer, the ganglion plexiform layer, the inner plexiform layer, and the inner nuclear layer) can be detected in HM849II13 and HM862II11. The macular structure of HM878II3 was normal.

564
retinal abnormalities (i.e., lattice degeneration, retinal holes, or retinal detachment), and cleft palate (Table 2).

To test whether there were age-dependent differences for clinical signs associated with mutations in \textit{COL2A1} or \textit{COL11A1}, comparisons of clinical data were also performed between the probands and their affected family members. There were statistically significant differences in age ($p = 1.80 \times 10^{-8}$), HJ (11/12 versus 3/14; $p = 3.42 \times 10^{-4}$) and retinal abnormalities ($p = 0.02$). In addition, older patients had a higher frequency of vitreous opacity, retinal abnormalities (lattice degeneration, retinal holes, and retinal detachment), and musculoskeletal abnormalities, as seen in the family members (Table 3). However, these diagnostic signs were either absent or not obvious in early childhood, as in most probands.

PVD/FH and HJ are frequent specific signs in children with eoHM and mutations in \textit{COL2A1} or \textit{COL11A1}; therefore, these two signs may be considered early suggestive signs for
STL. In addition, as eoHM is easily recognizable and more frequent than vitreous opacity and retinal abnormalities in young patients, eoHM might be an earlier suggestive sign for STL. The proportion of patients carrying eoHM and HJ to patients carrying all signs (eoHM, HJ, and PVD/FH) was statistically significantly higher in younger probands than in family members with mutations in COL2A1 or COL11A1 (11/12 versus 3/14, p = 3.42 × 10⁻⁴; 9/12 versus 3/14, p = 6.32 × 10⁻³) and controls with eoHM without mutations in COL2A1 or COL11A1 (11/12 versus 3/30, p = 3.94 × 10⁻⁷; 9/12 versus 0/30, p = 8.73 × 10⁻⁷; Table 4). This further supports the idea that eoHM, HJ, and PVD/FH are important clues for STL.

**Table 2. Comparisons of clinical data eoHM patients with mutations compared to eoHM controls without mutations.**

| Parameter                  | Patients with mutations n=26 | Controls without mutations n=30 | Comparison  
|----------------------------|------------------------------|---------------------------------|-------------  
| Age (Y)                    | 24.04±16.46                 | 17.53±13.18                     | 0.10         
| eoHM                       | 23 (88.5)                   | 30 (100.0)                      | 0.06         
| Refractive error           | -10.92±6.94                 | -9.08±4.32                      | 0.23         
| Axial length               | 27.06±2.25                  | 27.12±2.64                      | 0.93         
| PVD/FH                     | 22 (84.6)                   | 8 (26.7)                        | 1.40E-05     
| Vitreous opacity           | 9 (34.62)                   | 1 (3.3)                         | 2.30E-03     
| Retinal abnormality        | 5 (19.2)                    | 2 (6.7)                         | 0.16         
| Cleft palate               | 3 (11.5)                    | 0 (0)                           | 0.06         
| HJ                         | 14 (53.8)                   | 3 (10.0)                        | 3.72E-04     
| HJ (<16Y)                  | 12/12 (100.0)               | 3/18 (16.7)                     | 8.00E-06     

NO., number; Y, years; PVD, posterior vitreous detachment; FH, foveal hypoplasia; HJ, hypermobility of the elbow joint; † Percentages are based on the total number of the individuals.

**Table 3. Comparisons of clinical data between probands and affected family members with mutations.**

| Parameter                  | Probands n=12 | Family members n=14 | Comparison  
|----------------------------|---------------|---------------------|-------------  
| Age (Y)                    | 8.91±4.03     | 37.00±11.18         | 1.80E-08     
| eoHM                       | 12 (100.0)    | 11 (78.6)           | 0.09         
| Refractive error           | -9.53±7.14    | -13.60±6.17         | 0.13         
| Axial length               | 27.72±1.88    | 26.35±2.40          | 0.12         
| PVD/FH                     | 9 (75.0)      | 13 (92.9)           | 0.21         
| Vitreous opacity           | 2 (16.7)      | 7 (50.0)            | 0.08         
| Retinal abnormality        | 0 (0.0)       | 5 (35.7)            | 0.02         
| HJ                         | 11 (91.7)     | 3 (21.4)            | 3.42E-04     
| HJ (<16Y)                  | 11/11 (100.0) | 1/1 (100.0)         | 1.00         

Other signs of STL diagnostic criteria

| Parameter                  | NO. (%)†  
|----------------------------|-----------  
| Orofacial abnormality      | 10 (83.3) | 0.47  
| Musculoskeletal abnormality| 3 (25.0)  | 0.10  
| Hearing loss               | 5 (41.7)  | 0.67  

**Diagnosis of STL after follow-up exam**  

| Parameter                  | NO. (%)‡  
|----------------------------|-----------  
| Diagnosis of STL           | 3 (25.0)  | 0.19  
| Diagnosis of STL if new signs added| 8 (66.7)  | 0.09  

NO., number; Y, years; PVD, posterior vitreous detachment; FH, foveal hypoplasia; HJ, hypermobility of the elbow joint; † Percentages are based on the total number of the individuals. ‡ eoHM, PVD/FH and HJ were added as one point each in the suggested criteria. § One proband was too young to undergo an auditory examination, and the data were not available.
As for the phenotypic overview, clinical data from 595 patients were retrieved from the literature, including 380 patients with STL1 caused by mutations in COL2A1 (except the mutations in exon 2 in COL2A1), 52 patients with ocular-only STL1 with mutations in exon 2 of COL2A1, 111 patients with STL2 caused by mutations in COL11A1, and 52 patients with Marshall syndrome caused by mutations in COL11A1 [15,17,18,25,27-29,32,35-90]. The phenotypic overview of the 595 patients with COL2A1 or COL11A1 mutations is summarized in Appendix 1. The overview showed that myopia and orofacial abnormality are the most common signs, affecting 71.4% (425/595) and 60.0% (357/595) of patients, respectively. Vitreous opacity, hearing loss, and musculoskeletal abnormality were reported in 38.3% (228/595), 36.1% (215/595), and 30.9% (184/595) of patients, respectively. For those four subtypes of STL (STL1, ocular-only STL1, STL2, and Marshall syndrome), systemic signs are less frequent in ocular-only STL1 compared to the other three subtypes. The incidence of hearing loss in STL2 is higher than in STL1, as mentioned in a previous review [91]. Membranous and beaded vitreous abnormality might be a clue for distinguishing STL1 from STL2 [13], but few reports have clarified the type of vitreous abnormality. The prevalence of hearing loss, orofacial abnormality, hypertelorism, and short stature is higher in Marshall syndrome than in STL1 and STL2. However, hypertelorism and short stature might be rarely recognized as specific signs for certain populations. The pattern of major signs seen in the 14 adults in the present study was comparable to that of STL1 in an overview, while vitreous abnormality, hearing loss, and skeletal abnormality were more common in adults than in children with eoHM and STL mutations in the present study (Appendix 1). The overview of the phenotype might assist clinicians in identifying patients whose condition may be caused by mutations in COL2A1 or COL11A1.

### DISCUSSION

In this study, follow-up examinations were performed on 12 probands and 14 affected family members with eoHM and mutations in COL2A1 or COL11A1. The resulting clinical data were compared with 30 patients with eoHM without mutations in COL2A1 or COL11A1. None of the 12 probands met the diagnostic criteria for STL [27] based on a review of their medical records from their initial visits. Even after comprehensive follow-up reexaminations based on the diagnostic criteria for STL, the clinical data for most of the 26 patients (16/26 for all, 9/12 for probands, 7/14 for affected family members) still did not meet the diagnostic criteria for STL. These results suggest that a diagnosis of STL based on previous criteria is still challenging in routine clinical practice. This is especially true for children presenting with HM in an eye clinic, even after follow-up examinations with reference to the diagnostic criteria of STL and after the identification of the causative mutations in COL2A1 or COL11A1.

Some of the previously described signs, such as flat or broad and round facial features, are commonly seen in the general population living in Southeast Asia [47,92,93]. Therefore, certain characteristic facial features, such as malar hypoplasia, a broad or flat nasal bridge, and micrognathia or retrognathia, might be not considered diagnostic signs of STL in such a population [47]. Other additional easily recognizable clues may help ophthalmologists identify STL without typical phenotypes.

Comparing the 26 patients harboring COL2A1 or COL11A1 mutations to 30 patients with eoHM without...
mutations revealed suggestive signs that could be helpful in warning a patient about a potential diagnosis of STL. EoHM seemed to be present in all the probands with mutations in COL2A1 or COL11A1, but this study demonstrated that mutations in STL-related genes are the most common cause of eoHM. This finding is identical to the overview of the phenotype of patients with mutations in COL2A1 or COL11A1 (Appendix 1). EoHM is the earliest presenting and most easily recognizable sign for children with potential STL. Specific ocular signs of STL, including characteristic vitreous changes or retinal abnormalities (lattice degeneration, retinal hole, retinal detachment, or retinal tear), were rarely present in children with eoHM and mutation in COL2A1 or COL11A1 in this cohort (Table 3 and Appendix 2). Therefore, keeping eoHM in mind as a common presenting sign of STL could facilitate the identification of children with potential STL at eye clinics.

Two additional new signs were frequently observed in probands with eoHM with mutations in COL2A1 or COL11A1, that is, PVD/FH and HJ. A child with eoHM plus HJ is highly likely to have STL when compared to controls without STL with eoHM (Table 4). HJ can be easily observed in a routine clinic without any instruments or additional fees. HJ is an age-dependent sign that usually presents in affected children but rarely in affected adults. In addition, PVD/FH based on an OCT scan may provide additional evidence for STL (Table 4), which supports recently reported findings [94]. Thus, adding these three signs as new diagnostic clues may facilitate the clinical diagnosis of STL (Table 3).

The present study is limited by the lack of auditory and comprehensive musculoskeletal data from controls with eoHM without mutations in COL2A1 or COL11A1. As an eye hospital without facilities for auditory examination, we are unable to refer patients for auditory tests at other hospitals if the patients do not present related signs or symptoms. Additionally, we are unable to refer patients for X-rays if the patients do not present related signs or symptoms.

In summary, some patients with STL may present as having eoHM at the clinic, and a considerable proportion of patients are actually patients with STL with atypical phenotypes. This further supports the great phenotypic variation of STL [18,26,28,29]. Mutations in exon 2 of COL2A1 have been suggested to cause nonsyndromic ocular STL, even when systemic features are mild or even absent [34]. Mutations in other regions of COL2A1 may also cause atypical STL with mainly ocular phenotypes [72], especially in the early stage. Nevertheless, HJ and PVD/FH, in addition to eoHM, may provide additional evidence suggestive of atypical STL in an eye clinic. Gene tests on suspected cases may provide a firm diagnosis of STL. Tests of suspected cases with other atypical signs may expand our knowledge of the phenotypic variation of STL, as well as the prevalence of STL in the general population, which might be greatly underestimated.

APPENDIX 1. SUPPLEMENTAL FIGURE 1.
A: Comparisons of the phenotypes between patients in our study and previous studies (STL1, ocular-only STL, STL2, and Marshall Syndrome). B: Comparisons of the phenotypes between children and adults with eoHM harboring STL mutations. VO, vitreous opacity; RD, retinal detachment; HL, hearing loss; Skel, skeletal abnormality; HJ, joint hypermobility. To access the data, click or select the words “Appendix 1.”

APPENDIX 2. SUPPLEMENTAL TABLE 1.
Clinical data of the 12 probands and 14 affected family members from follow-up examination after identification of mutations. To access the data, click or select the words “Appendix 2.”

ACKNOWLEDGMENTS
This study was supported by grants from the Natural Science Foundation of Guangdong (S2013030012978), the Key Projects of Guangzhou (201607020013), and the Fundamental Research Funds of the State Key Laboratory of Ophthalmology. We thank the patients and their family members for their participation.

REFERENCES
1. Young TL, Metlapally R, Shay AE. Complex trait genetics of refractive error. Arch Ophthalmol. 2007;125:38-48. [PMID: 17210850].
2. Percival SP. Redefinition of high myopia: the relationship of axial length measurement to myopic pathology and its relevance to cataract surgery. Dev Ophthalmol 1987;14:42-6. [PMID: 3653484].
3. Zhang Q, Guo X, Xiao X, Jia X, Li S, Hejtmancik JF. Novel locus for X linked recessive high myopia maps to Xq23-q25 but outside MYP1. J Med Genet 2006;43:e20-[PMID: 16648373].
4. Sun W, Huang L, Xu Y, Xiao X, Li S, Jia X, Gao B, Wang P, Guo X, Zhang Q. Exome Sequencing on 298 Probands With Early-Onset High Myopia: Approximately One-Fourth Show Potential Pathogenic Mutations in RetNet Genes. Invest Ophthalmol Vis Sci 2015;56:8365-72. [PMID: 26747767].
5. Li J, Zhang Q. Insight into the molecular genetics of myopia. Mol Vis 2017;23:1048-80. [PMID: 28936878].
6. Lee JK, Kim H, Park YM, Kim DH, Lim HT. Mutations in DZIP1 and XYLT1 are associated with nonsyndromic early onset high myopia in the Korean population. Ophthalmic Genet 2017; 38:395-7. [PMID: 28085539].

7. Zhou L, Xiao X, Li S, Jia X, Zhang Q. Frequent mutations of RetNet genes in eOHM: Further confirmation in 325 probands and comparison with late-onset high myopia based on exome sequencing. Exp Eye Res 2018; 171:76-91. [PMID: 29453956].

8. Wu PC, Huang HM, Yu HJ, Fang PC, Chen CT. Epidemiology of Myopia. Asia Pac J Ophthalmol (Phila) 2016; 5:386-93. [PMID: 27898441].

9. Lin Z, Vasudevan B, Jhanji V, Mao GY, Gao TY, Wang FH, Rong SS, Ciufrreda KJ, Liang YB. Near work, outdoor activity, and their association with refractive error. Optom Vis Sci 2014; 91:376-82. [PMID: 24637483].

10. Jin ZB, Wu J, Huang XF, Feng CY, Cai XB, Mao JY, Xiang L, Wu KC, Xiao X, Kloss BA, Li Z, Liu Z, Huang S, Shen M, Cheng FF, Cheng XW, Zheng ZL, Chen X, Zhuang W, Zhang Q, Young TL, Xie T, Lu F, Qu J. Trio-based exome sequencing arrests de novo mutations in early-onset high myopia. Proc Natl Acad Sci USA 2017; 114:4219-24. [PMID: 28373534].

11. Xiao X, Li S, Jia X, Guo X, Zhang Q. X-linked heterozygous mutations in ARR3 cause female-limited early onset high myopia. Mol Vis 2016; 22:1257-66. [PMID: 27829781].

12. Li J, Gao B, Xiao X, Li S, Jia X, Sun W, Guo X, Zhang Q. Exome sequencing identified null mutations in LOXL3 associated with early-onset high myopia. Mol Vis 2016; 22:161-7. [PMID: 26957899].

13. Robin NH, Moran RT, Ala-Kokko L. Stickler Syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Beaudet AL, Meese EM, Monaghan MM, eds. GeneReviews [Internet]; 2001 [cited 2018 May 12]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1203/

14. Priya J, Joshii S. Marshall syndrome. Indian Pediatr 2005; 42:177-8. [PMID: 15767717].

15. Majava M, Hoomaart KP, Bartholdi D, Bouma MC, Bouman K, Carrera M, Devriendt K, Harust J, Kittos G, Niedrist D, Petersen MB, Shears D, Stolte-Dijkstra I, Van Hagen JM, Ala-Kokko L, Mannnikko M, Mortier GR. A report on 10 new patients with heterozygous mutations in the COL11A1 gene and a review of genotype-phenotype correlations in type XI collagenopathies. Am J Med Genet A 2007; 143A:258-64. [PMID: 17236192].

16. Melkoniemi M, Koillinen H, Mannnikko M, Warman ML, Pihlajamaa T, Kaariainen H, Rautio J, Hukki J, Stofko JA, Cisneros GJ, Krakow D, Cohn DH, Kere J, Ala-Kokko L. Collagen XI sequence variations in nonsyndromic cleft palate, Robin sequence and micrognathia. Eur J Hum Genet 2003; 11:265-70. [PMID: 12673280].

17. Ahmad NN, McDonald-McGinn DM, Zackai EH, Knowlton RG, LaRossa D, DiMascio J, Prockop DI. A second mutation in the type I procollagen gene (COL2A1) causing stickler syndrome (arthro-ophthalmopathy) is also a premature termination codon. Am J Hum Genet 1993; 52:39-45. [PMID: 8434604].

18. Annunen S, Korkko J, CZarny M, Warman ML, Brunner HG, Kaariainen H, Mulliken JB, Tranjbjaerg L, Brooks DG, Cox GF, Cruesberg JR, Curtis MA, Davenport SL, Friedrich CA, Kaitila I, Krawczynski MR, Latos-Bielenska A, Mukai S, Olsen BR, Shinno N, Sumer M, Vikkula M, Zlotogora J, Prockop DJ, Ala-Kokko L. Splicing mutations of 54-bp exons in the COL11A1 gene cause Marshall syndrome, but other mutations cause overlapping Marshall/Stickler phenotypes. Am J Hum Genet 1999; 65:974-83. [PMID: 10486316].

19. Pihlajamaa T, Prockop DJ, Faber J, Winterpacht A, Zabel B, Giedion A, Wiesbauer P, Spranger J, Ala-Kokko L. Heterozygous glycin substitution in the COL11A2 gene in the original patient with the Weissenbacher-Zweymuller syndrome demonstrates its identity with heterozygous OSMD (nonocular Stickler syndrome). Am J Med Genet 1998; 80:115-20. [PMID: 9805126].

20. Nikopoulos K, Schrauwen I, Simon M, Collin RW, Veckeneer M, Keymolen K, Van Camp G, Cremers FP, van den Born LI. Autosomal recessive Stickler syndrome in two families is caused by mutations in the COL9A1 gene. Invest Ophthalmol Vis Sci 2011; 52:4774-9. [PMID: 21421862].

21. Baker S, Booth C, Fillman C, Shapiro M, Blair MP, Hyland JC, Ala-Kokko L. A loss of function mutation in the COL9A2 gene causes autosomal recessive Stickler syndrome. Am J Med Genet A 2011; 155A:1668-72. [PMID: 21671392].

22. Goldstein O, Guyon R, Kukekova A, Kuznetsova TN, Pearce-Kelling SE, Johnson J, AGuirre GD, Acland GM, COL9A2 and COL9A3 mutations in canine autosomal recessive oculoskeletal dysplasia. Mamm Genome 2010; 21:398-408. [PMID: 20686772].

23. Alzahrani F, Al Hazzaa SA, Tayeb H, Alkuraiya FS, LOXL3, encoding lysyl oxidase-like 3, is mutated in a family with autosomal recessive Stickler syndrome. Hum Genet 2015; 134:451-3. [PMID: 25663169].

24. Zhang J, Yang R, Liu Z, Hou C, Zong W, Zhang A, Sun X, Gao J. Loss of lysyl oxidase-like 3 causes cleft palate and spinal deformity in mice. Hum Mol Genet 2015; 24:6174-85. [PMID: 26307084].

25. Nishimura G, Haga N, Kito H, Tanaka Y, Sonoda T, Kitamura M, Shirahama S, Itoh T, Nakashima E, Ohashi H, Ikegawa S. The phenotypic spectrum of COL2A1 mutations. Hum Mutat 2005; 26:36-43. [PMID: 15895462].

26. Snead MP, Yates JR. Clinical and Molecular genetics of Stickler syndrome. J Med Genet 1999; 30:535-39. [PMID: 10353778].

27. Rose PS, Levy HP, Liberfarb RM, Davis J, Szymko-Bennett Y, Rubin BJ, Tislov E, Griffith AJ, Franchonano CA. Stickler syndrome: clinical characteristics and diagnostic criteria. Am J Med Genet A 2005; 138A:199-207. [PMID: 16152640].

28. Liberfarb RM, Levy HP, Rose PS, Wilkin DJ, Davis J, Balog JZ, Griffith AJ, Szymko-Bennett YM, Johnston JJ, Franchonano CA, Tislov E, Rubin BI. The Stickler syndrome: genotype-phenotype correlation in 10 families with Stickler syndrome resulting from seven mutations in the type II
collagen gene locus COL2A1. Genet Med 2003; 5:21-7. [PMID: 12544472].

29. Richards AJ, Baguley DM, Yates JR, Lane C, Nicol M, Harper PS, Scott JD, Sneed MP. Variation in the vitreous phenotype of Stickler syndrome can be caused by different amino acid substitutions in the X position of the type II collagen Gly-X-Y triple helix. Am J Hum Genet 2000; 67:1083-94. [PMID: 11007540].

30. Brunner HG, van Beersum SE, Warman ML, Olsen BR, Ropers HH, Mariman EC. A Stickler syndrome gene is linked to chromosome 6 near the COL11A2 gene. Hum Mol Genet 1994; 3:1561-4. [PMID: 7833911].

31. Sirko-Osadsa DA, Murray MA, Scott JA, Lavery MA, Warman ML, Robin NH. Stickler syndrome without eye involvement is caused by mutations in COL11A2, the gene encoding the alpha2(XI) chain of type XI collagen. J Pediatr 1998; 132:368-71. [PMID: 9506662].

32. Richards AJ, Martin S, Yates JR, Scott JD, Baguley DM, Pope FM, Sneed MP. COL2A1 exon 2 mutations: relevance to the Stickler and Wagner syndromes. Br J Ophthalmol 2000; 84:364-71. [PMID: 10729292].

33. Parma ES, Korkko J, Hagler WS, Ala-Kokko L. Radial perivascular retinal degeneration: a key to the clinical diagnosis of an oculocutaneous variant of Stickler syndrome with minimal or no systemic manifestations. Am J Ophthalmol 2002; 134:728-34. [PMID: 12429250].

34. Sneed MP, McNinch AM, Poulsom AV, Beacroft P, Silverman B, Gomersall P, Parfect V, Richards AJ. Stickler syndrome, ocular-only variants and a key diagnostic role for the ophthalmologist. Eye (Lond) 2011; 25:1389-400. [PMID: 21921955].

35. Savasta S, Salpietro V, Sparta MV, Foadielli T, Laino D, Lobefalo L, Marsegla GL, Verrotti A. Stickler syndrome associated with epilepsy: report of three cases. Eur J Pediatr 2015; 174:697-701. [PMID: 25809783].

36. Yoon JM, Jang MA, Ki CS, Kim SJ. Two Likely Pathogenic Variants of COL2A1 in Unrelated Korean Patients With Oculocutaneous Variants of Stickler Syndrome: The First Molecular Diagnosis in Korea. Ann Lab Med 2016; 36:166-9. [PMID: 26709265].

37. Tran-Viet KN, Soler V, Quetier V, Powell C, Yanovitch T, Metlapally R, Luo X, Katsanis N, Nading E, Young TL. Mutation in collagen II alpha 1 isoforms delineates Stickler and Wagner syndrome phenotypes. Mol Vis 2013; 19:759-66. [PMID: 23592912].

38. Dupont C, Baumann M, Le Du N, Schaefer E, Guimiot F, Boutaud L, Capri Y, Spaggiari E, Aboura A, Benzacken B, Tabet AC. COL2A1 gene disruption by a balanced translocation t(12;15)(q13;q22.2) in familial Stickler syndrome. Am J Med Genet A 2013; 161A:2663-5. [PMID: 23918474].

39. Nagendran S, Richards AJ, McNinch A, Sandford RN, Sneed MP. Somatic mosaicism and the phenotypic expression of COL2A1 mutations. Am J Med Genet A 2012; 158A:1204-7. [PMID: 22496037].

40. Richards AJ, McNinch A, Whittaker J, Treacy B, Oakhill K, Poulsom A, Sneed MP. Splicing analysis of unclassified variants in COL2A1 and COL11A1 identifies deep intronic pathogenic mutations. Eur J Hum Genet 2012; 20:552-8. [PMID: 22189268].

41. Segers H, Kersseboom R, Alders M, Pieters R, Wagner A, van den Heuvel-Eibrink MM. Frequency of WT1 and 1p15 constitutional aberrations and phenotypic correlation in childhood Wilms tumour patients. Eur J Cancer 2012; 48:3249-56. [PMID: 22796116].

42. Stevenson DA, Vanzo R, Damjanovich K, Hanson H, Muntz H, Hoffman RO, Bayrak-Toydemir P. Mosaicism in Stickler syndrome. Eur J Med Genet 2012; 55:418-22. [PMID: 22522174].

43. Gerth-Kahlert C, Grisanti S, Berger E, Hohn R, Witt G, Jung U. Bilateral vitreous hemorrhage in a newborn with Stickler syndrome associated with a novel COL2A1 mutation. J AAPOS 2011; 15:311-3. [PMID: 21777803].

44. Yaguchi H, Ikeda T, Osada H, Yoshitake Y, Sasaki H, Yonekura H. Identification of the COL2A1 mutation in patients with type I Stickler syndrome using RNA from freshly isolated peripheral white blood cells. Genet Test Mol Biomarkers 2011; 15:231-7. [PMID: 2186996].

45. Hoornaert KP, Vereecke I, Dewinter C, Rosenberg T, Beemer FA, Leroy JG, Bendix L, Bjorck E, Bonduelle M, Boute O, Cormier-Daire V, De Die-Smulders C, Dieux-Coëslier A, Dollfus H, Elting M, Green A, Guerci V, Hennekam RC, Hihlorts-Hofstee Y, Holder M, Hoyal C, Jones KJ, Josifova D, Kaitila I, Kjaergaard S, Kroes YH, Lagerstedt K, Lees M, Lemerrer M, Magnani C, Marcelis C, Martorell L, Mathieu M, McEntagart M, Mendicino A, Morton J, Orazio G, Paquis V, Reish O, Simola KO, Smithson SF, Temple KL, Van Aken H, Van den Ende J, Van Hagen JM, Zelante L, Zordania R, De Paepe A, Leroy BP, De Buyzere M, Coucke PJ, Mortier GR. Stickler syndrome caused by COL2A1 mutations: genotype-phenotype correlation in a series of 100 patients. Eur J Hum Genet 2010; 18:872-80. [PMID: 20179744].

46. Zechi-Ceide RM, Jesus Oliveira NA, Guion-Almeida ML, Antunes LF, Richieri-Costa A, Passos-Bueno MR. Unusual phenotype in a female patient with a Gly25Ala substitution in the signal peptide region of the COL2A1 gene. Clin Dysmorphol 2008; 17:225-6. [PMID: 18541977].

47. McAlinden A, Majava M, Bishop PN, Perveen R, Black GC, Pierpont ME, Ala-Kokko L, Mannikko M. Missense and nonsense mutations in the alternatively-spliced exon 2 of COL2A1 cause the ocular variant of Stickler syndrome. Hum Mutat 2008; 29:83-90. [PMID: 17721977].

48. Richards AJ, Laidlaw M, Meredith SP, Shankar P, Poulsom AV, Scott JD, Sneed MP. Missense and silent mutations in COL2A1 result in Stickler syndrome but via different molecular mechanisms. Hum Mutat 2007; 28:639-48. [PMID: 17437277].

49. Yoshiida S, Yamaji Y, Kuwahara R, Yoshida A, Hisatomi T, Ueno A, Ishibashi T. Novel mutation in exon 2 of COL2A1.
gene in Japanese family with Stickler Syndrome type I. Eye (Lond) 2006; 20:743-5. [PMID: 16021188].

50. Richards AJ, Meredith S, Poulsen A, Bearcroft P, Crossland G, Baguley DM, Scott JD, Smed MP. A novel mutation of COL2A1 resulting in dominantly inherited rhemagmatogenous retinal detachment. Invest Ophthalmol Vis Sci 2005; 46:663-8. [PMID: 15671297].

51. Bajiens LW, De Leenheer EM, Weekamp HH, Cruysberg JR, Mortier GR, Cremers CW. Stickler syndrome type I and Stapes ankylosis. Int J Pediatr Otorhinolaryngol 2004; 68:1573-80. [PMID: 15533574].

52. Vu CD, Brown J Jr, Korkko J, Ritter R 3rd, Edwards AO. Posterior chorioretinal atrophy and vitreous phenotype in a family with Stickler syndrome from a mutation in the COL2A1 gene. Ophthalmology 2003; 110:70-7. [PMID: 12511349].

53. Leung L, Hyland JC, Young A, Goldberg MF, Handa JT. A novel mutation in intron 11 of the COL2A1 gene in a patient with type I Stickler syndrome. Retina 2006; 26:106-9. [PMID: 16395149].

54. Donoso LA, Edwards AO, Frost AT, Ritter R, Ahmad NN, Vrabec T, Rogers J, Meyer D. Identification of a stop codon mutation in exon 2 of the collagen 2A1 gene in a large stickler syndrome family. Am J Ophthalmol 2002; 134:720-7. [PMID: 12429249].

55. Freddi S, Savarirayan R, Bateman JF. Molecular diagnosis of Stickler syndrome: a COL2A1 stop codon mutation screening strategy that is not compromised by mutant mRNA instability. Am J Med Genet 2000; 90:398-406. [PMID: 10706362].

56. Faber J, Winterpacht A, Zabel B, Gnoinski W, Schinzel A, Steinmann B, Superti-Furga A. Clinical variability of Stickler syndrome with a COL2A1 haploinsufficiency mutation: implications for genetic counselling. J Med Genet 2000; 37:318-20. [PMID: 10819645].

57. Korkko J, Ritvaniemi P, Haataja L, Kaariainen H, Kivirikko KI, Prokop DJ, Ala-Kokko L. Mutations in type II procollagen (COL2A1) that substitutes aspartate for glycine alpha 1–67 and that causes cataracts and retinal detachment: evidence for molecular heterogeneity in the Wagner syndrome and the Stickler syndrome (arthro-ophthalmpathy). Am J Hum Genet 1993; 53:55-61. [PMID: 8317498].

58. Ballo R, Beighton PH, Ramesar RS. Stickler-like syndrome due to a dominant negative mutation in the COL2A1 gene. Am J Med Genet 1998; 80:6-11. [PMID: 9800905].

59. Ahmad NN, Ala-Kokko L, Knowlton RG, Jimenez SA, Weaver EJ, Maguire JJ, Tasman W, Prokop DJ. Stop codon in the procollagen II gene (COL2A1) in a family with the Stickler syndrome (arthro-ophthalmopathy). Proc Natl Acad Sci USA 1991; 88:6624-7. [PMID: 1677770].

60. Brown DM, Vandenhburgh K, Kimura AE, Weingeist TA, Sheffield VC, Stone EM. Novel frameshift mutations in the procollagen 2 gene (COL2A1) associated with Stickler syndrome (hereditary artho-ophthalmopathy). Hum Mol Genet 1995; 4:141-2. [PMID: 7711727].

61. Ritvaniemi P, Hyland J, Ignatius J, Kivirikko KI, Prokop DJ, Ala-Kokko L. A fourth example suggests that premature termination codons in the COL2A1 gene are a common cause of the Stickler syndrome: analysis of the COL2A1 gene by denaturing gradient gel electrophoresis. Genomics 1993; 17:218-21. [PMID: 8406454].

62. Higuchi Y, Hasegawa K, Yamashita M, Tanaka H, Tsukahara H. A novel mutation in the COL2A1 gene in a patient with Stickler syndrome type 1: a case report and review of the literature. J Med Case Reports 2017; 11:237- [PMID: 28841907].

63. Kondo H, Matsushita I, Nagata T, Hayashi T, Kakinoki M, Uchio E, Kondo M, Ohji M, Kusaka S. Novel mutations in the COL2A1 gene in Japanese patients with Stickler syndrome. Hum Genom Var 2016; 3:16018-. [PMID: 27408751].

64. Tompson SW, Johnson C, Abbott D, Bakall B, Soler V, Yano-vitch TL, Whisenhunt KN, Klemm T, Rozen S, Stone EM, Johnson M, Young TL. Reduced penetrance in a large Caucasian pedigree with Stickler syndrome. Ophthalmic Genet 2017; 38:43-50. [PMID: 28095098].

65. Goyal M, Kapoor S, Ikegawa S, Nishimura G. Stickler Syndrome Type I with Short Stature and Atypical Ocular Manifestations. Case Rep Pediatr 2016; 2016:3198597. [PMID: 28018693].

66. Wang X, Jia X, Xiao X, Li S, Li J, Li Y, Wei Y, Liang X, Guo X. Mutation survey and genotype-phenotype analysis of COL2A1 and COL11A1 genes in 16 Chinese patients with Stickler syndrome. Mol Vis 2016; 22:697-704. [PMID: 27390512].

67. Zechi-Ceide RM, Jesus Oliveira NA, Guion-Almeida ML, Antunes LF, Richieri-Costa A, Passos-Bueno MR. Clinical evaluation and COL2A1 gene analysis in 21 Brazilian families with Stickler syndrome: identification of novel mutations, further genotype/phenotype correlation, and its implications for the diagnosis. Eur J Med Genet 2008; 51:183-96. [PMID: 18276201].

68. Olavarrieta L, Morales-Angulo C, del Castillo I, Moreno F, Moreno-Pelayo MA. Stickler and branchio-oto-renal syndromes in a patient with mutations in EYA1 and COL2A1 genes. Clin Genet 2008; 73:262-7. [PMID: 18177466].

69. Ang A, Ung T, Puvanachandra N, Wilson L, Howard F, Ryalls M, Richards A, Meredith S, Laidlaw M, Poulson A, Scott J, Snead M. Vitreous phenotype: a key diagnostic sign in Stickler syndrome types 1 and 2 complicated by double heterozygosity. Am J Med Genet A 2007; 143A:604-7. [PMID: 17318849].

70. MacRae ME, Patel DV, Richards AJ, Snead MP, Tolmie J, Lee WR. Type 1 Stickler syndrome: a histological and ultrastructural study of an untreated globe. Eye (Lond) 2006; 20:1061-7. [PMID: 16327798].

71. Hoornaert KP, Dewinter C, Vereecke I, Beemer FA, Courtens W, Fryer A, Fryssira H, Lees M, Mullner-Eidenbock A, Rimond DL, Siderius L, Superti-Furga A, Temple K, Willems PJ, Zankl A, Zieher C, De Paepe A, Coucke P, Mortier GR. The phenotypic spectrum in patients with arginine to
cysteine mutations in the COL2A1 gene. J Med Genet 2006; 43:406-13. [PMID: 16155195].

72. Go SL, Maugeri A, Mulder JJ, van Driel MA, Cremers FP, Hooy CB. Autosomal dominant rhematogenous retinal detachment associated with an Arg453Ter mutation in the COL2A1 gene. Invest Ophthalmol Vis Sci 2003; 44:4035-43. [PMID: 12939326].

73. Brown DM, Nichols BE, Weingeist TA, Sheffield VC, Kimura AE, Stone EM. Procollagen II gene mutation in Stickler syndrome. Arch Ophthalmol 1992; 110:1589-93. [PMID: 1444917].

74. Richards AJ, Morgan J, Bearcroft PWP, Pickering E, Owen MJ, Holmans P, Williams N, Tysoe C, Pope FM, Snead MP, Hughes H. Vitreoretinopathy with phalanegal epiphyseal dysplasia, a type II collagenopathy resulting from a novel mutation in the C-propeptide region of the molecule. J Med Genet 2002; 39:661-5. [PMID: 12205109].

75. Wilkin DJ, Liberfarb R, Davis J, Levy HP, Cole WG, Francomano CA, Cohn DH. Rapid determination of COL2A1 mutations in individuals with Stickler syndrome: Analysis of potential premature termination codons. Am J Med Genet 2000; 94:141-8. [PMID: 10982970].

76. Edwards TL, Burt BO, Black GCM, Perveen R, Kearns LS, Staffieri SE, Toomes C, Buttery RG, Mackey DA. Familial retinal detachment associated with COL2A1 exon 2 and FZD4 mutations. Clin Experiment Ophthalmol 2012; 40:476-83. [PMID: 22574936].

77. Suemori S, Sawada A, Shiraki I, Mochizuki K. Stickler syndrome type I accompanied by membranous vitreous anomaly in two Japanese sisters. Semin Ophthalmol 2014; 29:45-7. [PMID: 24164106].

78. Martin S, Richards AJ, Yates JR, Scott JD, Pope M, Snead MP. Stickler syndrome: further mutations in COL11A1 and evidence for additional locus heterogeneity. Eur J Hum Genet 1999; 7:807-14. [PMID: 10573014].

79. Hufnagel SB, Weaver KN, Hufnagel RB, Bader PL, Schorry EK, Hopkin RJ. A novel dominant COL11A1 mutation resulting in a severe skeletal dysplasia. Am J Med Genet A 2014; 164A:2607-12. [PMID: 25091507].

80. Richards AJ, Fincham GS, McNinch A, Hill D, Poulson AV, Castle B, Lees MM, Moore AT, Scott JD, Snead MP. Alternative splicing modifies the effect of mutations in COL11A1 and results in recessive type 2 Stickler syndrome with profound hearing loss. J Med Genet 2013; 50:765-71. [PMID: 23922384].

81. Acke FR, Malfait F, Vanakker OM, Steyaert W, De Leeeneer K, Mortier G, Dhooge I, De Paepe A, De Leenheer EM, Coucke PJ. Novel pathogenic COL11A1/COL11A2 variants in Stickler syndrome detected by targeted NGS and exome sequencing. Mol Genet Metab 2014; 113:230-5. [PMID: 25240749].

82. Vijzelaar R, Waller S, Errami A, Donaldson A, Lourenco T, Rodrigues M, McConnell V, Fincham G, Snead M, Richards A. Deletions within COL11A1 in Type 2 stickler syndrome detected by multiplex ligation-dependent probe amplification (MLPA). BMC Med Genet 2013; 14:48.-[PMID: 23621912].

83. Lauritsen KF, Lildhalle DL, Coucke PJ, Monrad R, Larsen DA, Gregersen PA. A mild form of Stickler syndrome type II caused by mosaicism of COL11A1. Eur J Med Genet 2017; 60:275-8. [PMID: 28315471].

84. Zhang H, Yang R, Wang Y, Ye J, Han L, Qiu W, Gu X. A pilot study of gene testing of genetic bone dysplasia using targeted next-generation sequencing. J Hum Genet 2015; 60:769-76. [PMID: 26377240].

85. Kohmoto T, Naruto T, Kobayashi H, Watanabe M, Okamoto N, Masuda K, Imoto I, Okamoto N. A novel COL11A1 mutation affecting splitting in a patient with Stickler syndrome. Hum Genome Var 2015; 2:15043.-[PMID: 27081549].

86. Poulson AV, Hooymans JM, Richards AJ, Bearcroft P, Murthy R, Baguley DM, Scott JD, Snead MP. Clinical features of type 2 Stickler syndrome. J Med Genet 2004; 41:e107.-[PMID: 15286167].

87. Vogiatzi MG, Li D, Tian L, Garifallou JP, Kim CE, Hakonarson H, Levine MA. A novel dominant COL11A1 mutation in a child with Stickler syndrome type II is associated with recurrent fractures. Osteoporos Int 2018; 29:247-51. [PMID: 28971234].

88. Richards AJ, Yates JR, Williams R, Payne SJ, Pope FM, Scott JD, Snead MP. A family with Stickler syndrome type 2 has a mutation in the COL11A1 gene resulting in the substitution of glycine 97 by valine in alpha 1 (XI) collagen. Hum Mol Genet 1996; 5:339-43. [PMID: 8872475].

89. Acke FR, Swinnen FK, Malfait F, Dhooge IJ, De Leenheer EM. Auditory phenotype in Stickler syndrome: results of audiometric analysis in 20 patients. Eur Arch Otorhinolaryngol 2016; 273:3025-34. [PMID: 26786361].

90. Ahmad N, Richards AJ, Murfett HC, Shapiro L, Scott JD, Yates JR, Norton J, Snead MP. Prevalence of mitral valve prolapse in Stickler syndrome. Am J Med Genet A 2003; 116A:234-7. [PMID: 12503098].

91. Acke FR, Dhooge IJ, Malfait F, De Leenheer EM. Hearing impairment in Stickler syndrome: a systematic review. Orphanet J Rare Dis 2012; 7:84.-[PMID: 23110709].

92. Ryu MH, Moon VA. High superficial musculoaponeurotic system facelift with finger-assisted facial spaces dissection for Asian patients. Aesthet Surg J 2015; 35:1-8. [PMID: 25568228].

93. Shirakabe Y, Suzuki Y, Lam SM. A new paradigm for the aging Asian face. Aesthetic Plast Surg 2003; 27:397-402. [PMID: 14648062].

94. Matsushita I, Nagata T, Hayashi T, Kimoto K, Kubota T, Ohji M, Kusaka S, Kondo H. Foveal Hypoplasia in Patients with Stickler Syndrome. Ophthalmology 2017; 124:896-902. [PMID: 28283280].
